Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Aganepag, a potent Prostanoid EP2 receptor agonist, exhibits remarkable selectivity with an EC50 of 0.19 nM, demonstrating no activity at the EP4 receptor. Its applications are primarily in the fields of wound healing, scar reduction, scar prevention, and the treatment and prevention of wrinkles.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 521,000 |
50 mg | 約6-8 週間 | ¥ 684,000 |
100 mg | 約6-8 週間 | ¥ 918,000 |
説明 | Aganepag, a potent Prostanoid EP2 receptor agonist, exhibits remarkable selectivity with an EC50 of 0.19 nM, demonstrating no activity at the EP4 receptor. Its applications are primarily in the fields of wound healing, scar reduction, scar prevention, and the treatment and prevention of wrinkles. |
ターゲット&IC50 | EP2:0.19 nM (EC50) |
In vitro | Aganepag (Compound 3), a powerful Prostanoid EP2 receptor agonist, exhibits an EC50 of 0.19 nM and lacks activity at the EP4 receptor. This compound is applicable in studies focused on wound healing, scar reduction and prevention, as well as the treatment and prevention of wrinkles[1]. |
別名 | AGN 210937 |
分子量 | 429.57 |
分子式 | C24H31NO4S |
CAS No. | 910562-18-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Aganepag 910562-18-4 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor AGN-210937 AGN 210937 AGN210937 Inhibitor inhibitor inhibit